The drug manufacturer will eliminate 174 research positions at its facility in Braine-l'Alleud as well as a further 44 in Slough, UK, explaining that the move is designed to streamline its research wing.
UCB also plans to rejig industrial development support and administrative services at the Braine site.
CEO Roch Doliveus said that: "UCB's ability to adapt is key to maintaining our competitiveness within the world of biopharma innovation,'' suggesting the firm sees the cuts as a way of sustaining its edge.
The latest cuts are not part of UCB’s SHAPE restructuring operation, which has already seen it eliminate 2,000 positions.
